Strategic Government Partnerships

Curia provides strategic partnerships and local expertise across drug discovery, development and manufacturing.

Based in Albany, NY, Curia is a global contract, development, manufacturing organization (CDMO). Through our network of 28 facilities, we offer key advantages to advance your drug research and manufacturing program, including faster decision making, reduced timelines and local regulatory expertise. For more than 30 years Curia has successfully partnered with biotech and pharmaceutical companies, government agencies and therapeutic-specific institutes to drive the discovery and development of new medicines. We mitigate common challenges and regulatory risks associated with offshoring of research programs. Read below to learn more about our strategic relationships with US government research agencies.


NIH Blueprint Neurotherapeutics Network (BPN)

Curia is pleased to be the preferred and sole provider of medicinal chemistry to the NIH Blueprint Neurotherapeutics Network (BPN). The BPN provides non-dilutive funding for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. Through the BPN program, investigators together with the NIH build a team and leverage Curia’s drug discovery and development experts to help them advance their basic research into human testing. Additional information on BPN can be found here.


National Cancer Institute’s (NCI’s) Experimental Therapeutics Chemical Biology Consortium (aka the NExT CBC)

Curia is also a member of the National Cancer Institute’s (NCI’s) Experimental Therapeutics Chemical Biology Consortium (aka the NExT CBC). Where we provide medicinal chemistry, protein chemistry, structural biology and various in vitro pharmacology services to help convert the visions of academic pioneers into next generation drugs for the treatment of cancers. Additional information on the NExT CBC program can be found here.


National Institute of Neurological Disorders and Stroke (NINDs)

Curia enjoys ongoing collaborations with NINDs (National Institute of Neurological Disorders and Stroke), the NIH and the NCI beyond those detailed above, where we provide best-in-class discovery services including protein expression and crystallography, medicinal chemistry and DMPK. These relationships have evolved over a number of years of engagement as a service provider to each of these government institutions or their primary contractor (Leidos).

Additional agencies with which Curia enjoys meaningful collaboration include the Department of Veterans’ Affairs, Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense.

For more information on any of the strategic partnerships above or to speak with a Curia expert, please complete this form.

Curia Global Trade Compliance in Drug Development

The increasing global trade of pharmaceutical products underscores the need for (bio)pharmaceutical companies to be well-versed in international trade requirements. This white paper explores the impact of factors like the COVID-19 pandemic on global trade, emphasizing the importance of a robust international trade compliance program. Beyond mitigating risks of governmental investigations and penalties, a well-established compliance program becomes a strategic advantage, fostering a comprehensive supply chain and cost management for drugs and medical devices. The collaboration with a CDMO equipped with a dedicated trade compliance team becomes a decisive factor in ensuring consistent planning, accurate cost estimation, and enhanced delivery timelines for materials shipped across borders.


Curia Global Trade Compliance in Drug Development

Curia Enters Cooperative Agreement with U.S. Government to Expand Sterile Fill-Finish Capability

March 9, 2022 — Curia announced a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Army Contracting Command to support the domestic production of injectable medicines.

View Press Release


Ready to move from idea to impact?